Join
Live feed
·
PRReleasevia Quantisnow
Cullinan Therapeutics Inc. logo

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
CGEM· Cullinan Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGEM (Cullinan Therapeutics Inc.) and more on Quantisnow.